The Role of Long Non-Coding RNAs in Ovarian Cancer Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Sep 28

PMID 39337410

Authors

Anna Golara

Mateusz Kozlowski

Aneta Cymbaluk-Ploska

Affiliations

Soon will be listed here.

Abstract

Among the most deadly malignancies that strike women worldwide, ovarian cancer is still one of the most common. The primary factor affecting a patient's survival is early lesion discovery. Unfortunately, because ovarian cancer is a sneaky illness that usually manifests as nonspecific symptoms only in advanced stages, its early detection and screening are challenging. A lot of research is being conducted on effective methods of diagnosing and treating ovarian cancer. Recently, non-coding RNAs (ncRNAs) have gained great popularity, which are considered to be the main regulators of many cellular processes, especially those occurring in cancer. LncRNAs are also being studied for their therapeutic use in the treatment of ovarian cancer and their use in diagnostics and as indicators of poor prognosis. In this article, we reviewed lncRNAs described in the literature that may play an important role in ovarian cancer.

Citing Articles

Quantitative Analysis of Pseudogene-Associated Errors During Germline Variant Calling.

Podvalnyi A, Kopernik A, Sayganova M, Woroncow M, Zobkova G, Smirnova A Int J Mol Sci. 2025; 26(1.

PMID: 39796219 PMC: 11719938. DOI: 10.3390/ijms26010363.

References

Li X, Yang H, Wang J, Li X, Fan Z, Zhao J . High level of lncRNA H19 expression is associated with shorter survival in esophageal squamous cell cancer patients. Pathol Res Pract. 2019; 215(11):152638. DOI: 10.1016/j.prp.2019.152638. View

Chan J, Tian C, Kesterson J, Monk B, Kapp D, Davidson B . Symptoms of Women With High-Risk Early-Stage Ovarian Cancer. Obstet Gynecol. 2022; 139(2):157-162. PMC: 9126568. DOI: 10.1097/AOG.0000000000004642. View

Chai Y, Liu J, Zhang Z, Liu L . HuR-regulated lncRNA NEAT1 stability in tumorigenesis and progression of ovarian cancer. Cancer Med. 2016; 5(7):1588-98. PMC: 4944886. DOI: 10.1002/cam4.710. View

Snyder M, Iraola-Guzman S, Saus E, Gabaldon T . Discovery and Validation of Clinically Relevant Long Non-Coding RNAs in Colorectal Cancer. Cancers (Basel). 2022; 14(16). PMC: 9405614. DOI: 10.3390/cancers14163866. View

Wu Y, Zhou Y, He J, Sun H, Jin Z . Long non-coding RNA H19 mediates ovarian cancer cell cisplatin-resistance and migration during EMT. Int J Clin Exp Pathol. 2020; 12(7):2506-2515. PMC: 6949588. View

Lan T, Yuan K, Yan X, Xu L, Liao H, Hao X . LncRNA SNHG10 Facilitates Hepatocarcinogenesis and Metastasis by Modulating Its Homolog SCARNA13 via a Positive Feedback Loop. Cancer Res. 2019; 79(13):3220-3234. DOI: 10.1158/0008-5472.CAN-18-4044. View

Jin Y, Wang H . Circ_0078607 inhibits the progression of ovarian cancer via regulating the miR-32-5p/SIK1 network. J Ovarian Res. 2022; 15(1):3. PMC: 8729016. DOI: 10.1186/s13048-021-00931-9. View

An J, Lv W, Zhang Y . LncRNA NEAT1 contributes to paclitaxel resistance of ovarian cancer cells by regulating ZEB1 expression via miR-194. Onco Targets Ther. 2017; 10:5377-5390. PMC: 5691924. DOI: 10.2147/OTT.S147586. View

Hu X, Yang L, Mo Y . Role of Pseudogenes in Tumorigenesis. Cancers (Basel). 2018; 10(8). PMC: 6115995. DOI: 10.3390/cancers10080256. View

10.

Endo I, Amatya V, Kushitani K, Nakagiri T, Aoe K, Takeshima Y . Long Non-coding RNA Requires to Promote Mesothelioma Cell Proliferation, Migration, and Invasion. Anticancer Res. 2023; 43(12):5367-5376. DOI: 10.21873/anticanres.16740. View

11.

Webb P, Jordan S . Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024; 21(5):389-400. DOI: 10.1038/s41571-024-00881-3. View

12.

Mattick J, Amaral P, Carninci P, Carpenter S, Chang H, Chen L . Long non-coding RNAs: definitions, functions, challenges and recommendations. Nat Rev Mol Cell Biol. 2023; 24(6):430-447. PMC: 10213152. DOI: 10.1038/s41580-022-00566-8. View

13.

Menon U, Gentry-Maharaj A, Burnell M, Ryan A, Singh N, Manchanda R . Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial. Lancet Oncol. 2023; 24(9):1018-1028. PMC: 7616829. DOI: 10.1016/S1470-2045(23)00335-2. View

14.

Zhou H, Shen W, Zou H, Lv Q, Shao P . Circulating exosomal long non-coding RNA H19 as a potential novel diagnostic and prognostic biomarker for gastric cancer. J Int Med Res. 2020; 48(7):300060520934297. PMC: 7361491. DOI: 10.1177/0300060520934297. View

15.

Hinchcliff E, Westin S, Herzog T . State of the science: Contemporary front-line treatment of advanced ovarian cancer. Gynecol Oncol. 2022; 166(1):18-24. DOI: 10.1016/j.ygyno.2022.04.021. View

16.

Wang B, Yang S, Zhao W . Long Non-Coding RNA NRAD1 and LINC00152 are Highly Expressed and Associated with Prognosis in Patients with Hepatocellular Carcinoma. Onco Targets Ther. 2020; 13:10409-10416. PMC: 7569076. DOI: 10.2147/OTT.S251231. View

17.

Grammatikakis I, Lal A . Significance of lncRNA abundance to function. Mamm Genome. 2021; 33(2):271-280. DOI: 10.1007/s00335-021-09901-4. View

18.

Bonifacio V . Ovarian Cancer Biomarkers: Moving Forward in Early Detection. Adv Exp Med Biol. 2020; 1219:355-363. DOI: 10.1007/978-3-030-34025-4_18. View

19.

Du W, Zhang C, Yang W, Yong T, Awan F, Yang B . Identifying and Characterizing circRNA-Protein Interaction. Theranostics. 2017; 7(17):4183-4191. PMC: 5695005. DOI: 10.7150/thno.21299. View

20.

Zhao L, Sun W, Zheng A, Zhang Y, Fang C, Zhang P . Ginsenoside Rg3 suppresses ovarian cancer cell proliferation and invasion by inhibiting the expression of lncRNA H19. Acta Biochim Pol. 2021; 68(4):575-582. DOI: 10.18388/abp.2020_5343. View